Key result
The implementation of a universal childhood hepatitis A vaccination program was associated with an increase in anti-HAV seroprevalence among children aged 1.5-7 years from 30.76% in 2006 to 77.46% in 2014.
Why the study?
The hepatitis A vaccine was included in China's national expanded program on immunization in 2008, prompting an evaluation of changes in the seroepidemiology of hepatitis A virus before and after program introduction.
Does the implementation of universal childhood hepatitis A vaccination improve anti-HAV seroprevalence in the general population?
Cross-Sectional (n=11,777)
Does the implementation of universal childhood hepatitis A vaccination improve anti-HAV seroprevalence in the general population?
The introduction of universal childhood hepatitis A vaccination in China significantly increased seroprevalence among children, though a decline in immunity among young adults highlights a potential vulnerable population.
This is the authors' abstract. We don't add key points for this paper.
OBJECTIVES: The hepatitis A vaccine (HepA) has been included in the national expanded program on immunization (EPI) in China since 2008. This study was performed to evaluate the change in dynamics of the seroepidemiology of hepatitis A virus (HAV) before and after the introduction of the program. METHODS: The trends in seroepidemiology of anti-HAV antibodies were examined in Shandong Province, China, drawing on two population-based samples of persons aged 1-59 years, one obtained in the year 2006 (n = 6682) and the other in 2014 (n = 5095). RESULTS: A dramatic increase in seroprevalence of anti-HAV antibodies from 30.76% (95% confidence interval (CI) 26.24-35.28%) to 77.46% (95% CI 74.04-80.87%) among children aged 1.5-7 years (born after HepA was recommended for routine childhood immunization), as well as an increase from 35.32% (95% CI 29.31-41.33%) to 66.69% (95% CI 55.59-77.80%) in subjects aged 8-14 years, was observed in 2014 when compared with 2006. By contrast, a decline in seroprevalence among subjects aged 15-29 years, as seen particularly in those 20-29 years of age, from 85.72% (95% CI 80.29-91.14%) to 69.24% (95% CI 62.02-76.45%), was found in this study. There was no statistically significant difference in seroprevalence between 2006 and 2014 among the subjects older than 30 years of age. CONCLUSIONS: The national HepA routine immunization program has had a positive effect, leading to an increase in anti-HAV seroprevalence among children in Shandong Province, China. More attention should be paid to young adults in the province.
Answers are grounded in this paper and cite their sources.
Supports childhood HAV vaccination in endemic settings; leaves open adult immunity durability and population-level impact.
No takes yet. Share an insight, caveat, or question.
Yan et al. (2019) conducted a cross-sectional in Hepatitis A (n=11,777). Year 2014 (post-universal childhood vaccination) vs. Year 2006 (pre-vaccination) was evaluated on Seroprevalence of anti-HAV antibodies among children aged 1.5-7 years. The implementation of a universal childhood hepatitis A vaccination program was associated with an increase in anti-HAV seroprevalence among children aged 1.5-7 years from 30.76% in 2006 to 77.46% in 2014.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: